Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease
Alzheimer's disease (AD) is a multifactorial irreversible neurological disorder which results
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …
Therapeutic targeting strategies for early-to late-staged Alzheimer's disease
Alzheimer's disease (AD) is the most common cause of dementia, typically showing
progressive neurodegeneration in aging brains. The key signatures of the AD progression …
progressive neurodegeneration in aging brains. The key signatures of the AD progression …
Update on the pharmacological treatment of Alzheimer's disease
F Massoud, S Gauthier - Current neuropharmacology, 2010 - ingentaconnect.com
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Worldwide
prevalence of the disease is estimated at more than 24 million cases. With aging of …
prevalence of the disease is estimated at more than 24 million cases. With aging of …
Pharmacotherapy evolution in Alzheimer's disease: current framework and relevant directions
Alzheimer's disease (AD), once considered a rare disease, is now the most common form of
dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate …
dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate …
Pharmacotherapy of Alzheimer's disease: Seeking clarity in a time of uncertainty
Alzheimer's disease (AD) is recognized as a major health hazard that mostly affects people
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …
Current trends and updates in the treatment of Alzheimer's disease
Alzheimer's disease (AD) is one the most prevalent multifactorial neurodegenerative
ailments of aging and is the leading cause of cognitive deficits with progressive impairment …
ailments of aging and is the leading cause of cognitive deficits with progressive impairment …
Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
Alzheimer's disease (AD) is the most common type of dementia accounting for 90% of cases;
however, frontotemporal dementia, vascular dementia, etc. prevails only in a minority of …
however, frontotemporal dementia, vascular dementia, etc. prevails only in a minority of …
Frontier on Alzheimer's Disease
C Cervellati, G Zuliani - International Journal of Molecular Sciences, 2023 - mdpi.com
Although substantial progress has been made in the last two decades, there are still
important unfilled gaps in the understanding of the pathomechanism of Alzheimer's disease …
important unfilled gaps in the understanding of the pathomechanism of Alzheimer's disease …
Impact of new drugs for therapeutic intervention in Alzheimer's disease
J Olloquequi, M Ettcheto, A Cano, E Sanchez-López… - 2022 - repositorio.uautonoma.cl
The increases in population ageing and growth are leading to a boosting in the number of
people living with dementia, Alzheimer's disease (AD) being the most common cause. In …
people living with dementia, Alzheimer's disease (AD) being the most common cause. In …
Advances in recent patent and clinical trial drug development for Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease, involving a large
number of genes, proteins and their complex interactions. Currently, no effective therapeutic …
number of genes, proteins and their complex interactions. Currently, no effective therapeutic …